11/7/2016 | HYIG | Market Commentary: Progenics Pharmaceuticals subsidiary gets $50 million 9½% loan from HealthCare Royalty
|
11/7/2016 | PV | New Issue: Progenics subsidiary MNTX secures $50 million via 9½% loan agreement
|
3/4/2014 | PP | Progenics greenshoe lifts public stock sale to $40.25 million
|
2/21/2014 | PP | Progenics prices $35 million public offering of common stock at $4.60
|
2/20/2014 | PP | Progenics announces plans to price public offering of common shares
|
1/24/2014 | PP | Progenics plans to conduct $50 million at-the-market equity offering
|
7/16/2013 | PP | Progenics greenshoe exercised for $43.01 million public sale of stock
|
6/20/2013 | PP | Progenics prices $37.4 million public sale of common stock at $4.40
|
6/19/2013 | PP | Progenics Pharmaceuticals intends to price public sale of common stock
|
11/29/2012 | PP | Progenics prices $22 million public offering of common stock at $2.00
|
11/28/2012 | PP | Progenics Pharmaceuticals to price public offering of common shares
|
8/11/2011 | CVHYPF | Progenics files $100 million shelf covering stock, debt and preferreds
|
11/5/2007 | SP | Natixis to price 20% reverse convertibles linked to Progenics for Eksportfinans
|
11/10/2006 | BT | Progenics kept at sector perform by RBC
|
11/10/2006 | BT | Merrill has Progenics at neutral
|
11/9/2006 | BT | Progenics quarterly revenues up $15 million from third-quarter 2005
|
11/7/2006 | BT | Merrill has Progenics at neutral
|
11/1/2006 | BT | Merrill keeps Progenics at neutral
|
9/20/2006 | BT | RBC keeps Progenics at sector perform
|
9/20/2006 | BT | Market Commentary: Incyte pitches deeply discounted drive-by convertible; Genta down 32% on PIPE; Adolor rises
|
9/20/2006 | BT | Progenics, Wyeth test intravenous methylnaltrexone in phase 3 trial
|
9/12/2006 | BT | Market Commentary: Oscient may bounce on expected FDA rejection; New River rises 6%; Adolor flat, Progenics lower
|
8/22/2006 | BT | Progenics kept at neutral by Merrill
|
8/22/2006 | BT | Wyeth, Progenics test oral methylnaltrexone in phase 2 trial
|
8/8/2006 | BT | Progenics kept at neutral by Merrill
|
8/8/2006 | BT | RBC rates Progenics at sector perform
|
7/27/2006 | BT | RBC initiates coverage of Progenics at sector perform
|
7/17/2006 | BT | Progenics maintained at neutral by Merrill
|
7/17/2006 | BT | Market Commentary: Threshold plunges over 51%; Genitope firms; Vivus dives; Progenics weak; Alnylam off
|
7/17/2006 | BT | Wyeth, Progenics: Methylnaltrexone receives fast-track status for treatment of postoperative ileus
|
6/6/2006 | BT | Wyeth, Progenics to test subcutaneous methylnalatrexone
|
5/31/2006 | BT | Merrill still neutral on Progenics
|
5/25/2006 | BT | Progenics broadens collaboration with Seattle Genetics for prostate cancer therapy
|
5/25/2006 | BT | Market Commentary: Cubist explodes ahead of Cubicin vote; Encysive advances; Seattle Genetics, Progenics gain on pact
|
5/24/2006 | BT | Merrill keeps Progenics at neutral
|
5/23/2006 | BT | Progenics reports methylnaltrexone shows benefits for opioid-induced constipation
|
5/10/2006 | BT | Progenics maintained at neutral by Merrill
|
4/24/2006 | BT | Cytogen sells ownership in joint venture to Progenics in deal valued at $65 million
|
4/24/2006 | BT | Market Commentary: DOV, Discovery Labs off huge after close; 3 deals emerge; GW up big; Ariad off on Amgen suit
|
4/21/2006 | BT | Progenics, Wyeth plan to file NDA for opioid receptor antagonist
|
4/21/2006 | BT | Merrill maintains Progenics at neutral rating
|
3/15/2006 | BT | Progenics fourth-quarter, year-end 2005 revenues down
|
2/22/2006 | BT | Progenics gets FDA fast track designation for PRO 140 HIV/AIDS drug
|
2/15/2006 | BT | Progenics says phase 3 trial of methylnaltrexone for constipation shows significant efficacy
|
2/15/2006 | BT | Merrill maintain Progenics at neutral
|
2/15/2006 | BT | Market Commentary: Pfizer peddling ¥50 billion bonds; Amgen up out of chute; Adolor at bat; Ranbaxy taps convertibles market
|
1/9/2006 | BT | Progenics Pharmaceuticals files shelf for 4 million shares
|
12/30/2005 | BT | Progenics still neutral, Merrill says
|
12/23/2005 | BT | Market Commentary: Progenics, Wyeth rise on $416.5 million pact; Par Pharma higher; AtheroGenics gains further 7%
|
12/23/2005 | CV | Market Commentary: Albertson's trades lower in active trade; Wyeth, Omnicare gain; GM sees light buying
|
12/23/2005 | BT | Progenics regains rights from licensees of MNTX, sells rights to Wyeth
|
12/23/2005 | BT | Progenics maintained by Merrill at neutral
|
12/5/2005 | BT | Progenics cut to neutral by Merrill Lynch
|
12/5/2005 | BT | Market Commentary: Noven soars on ADHD patch news; Ligand bounces on board expansion; Progenics off sharply
|
12/1/2005 | BT | Progenics Pharmaceuticals starts phase 1b trial of new HIV drug PRO 140
|
9/30/2005 | BT | Market Commentary: Predix IPO price range emerges; Genomic, Avalon, Sunesis a mix; Progenics up; BioDelivery slides
|
9/19/2005 | BT | Market Commentary: Viacell plunges on suspending study; StemCells rises on new filing; Inex drops on note demand
|
9/16/2005 | BT | Market Commentary: Meridian Biosciences slips in spot deal; Myogen, Geron deals show improved reception
|
9/14/2005 | BT | New Issue: Progenics raises $57.4 million in follow-on at $23.90, discounted from $25.02 close
|
9/14/2005 | BT | Market Commentary: Progenics off on spot sale; profits taken on Celgene rise; Cubist off; Access dives on bankruptcy fears
|
8/10/2005 | BT | Progenics reiterated by Merrill Lynch at buy
|
7/22/2005 | BT | Progenics maintained by Merrill at buy
|
7/14/2005 | BT | Progenics on the hunt for partner by year-end 2005
|
7/14/2005 | BT | Progenics initiated by Merrill at buy
|